Another study in 42 patients with HER2+ breast cancer, that used moDCs pulsed with six HER2 MHC class II binding peptides, could correlate pathologic complete response with the CD4+ Th1 immune response in the sentinel LN, but in peripheral blood (74). Here, ERBB2 is linked to breast cancer.